RTP biotech inks potential $400M deal with Bayer subsidiary


A biotech in Research Triangle Park has landed millions in cash through a new collaboration, with a chance to earn hundreds of millions more.

Previous Judge declines DOJ's request to halt Booz Allen's acquisition of Reston's EverWatch
Next Dyne founder heads up new RNA-editing startup